Coya Therapeutics completes Phase 2/3 enrollment for COYA 302 ALS trial

Coya announced full enrollment of 120 patients in the ALSTARS Phase 2/3 trial for COYA 302 in ALS treatment, with topline data expected in early Q2 2027. Enrollment completion is a concrete milestone that validates trial execution and moves the company closer to potential regulatory decision, reducing operational risk for an early-stage therapeutic company.

Coya finished recruiting all 120 patients needed for its mid-to-late stage trial testing a new ALS treatment, and will show results in early 2027. This is a key step forward for the company's product development.